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Objective: The relationship between fertilization rates and 1,25-dihydroxyvitamin D
(1,25(OH)2D3), 25-hydroxyvitamin D2 (25(OH)D2), 25-hydroxyvitamin D3 (25(OH)D3),
24,25-dihydroxyvitamin D (24,25(OH)2D3), and 25-hydroxy-3epi-Vitamin D3
(3epi25(OH)D3) concentrations in age and weight matched women with and without
PCOS was studied.
Methods: Fifty nine non-obese women, 29 with PCOS, and 30 non-PCOS undergoing
IVF, matched for age and weight were included. Serum vitamin D metabolites were taken
the menstrual cycle prior to commencing controlled ovarian hyperstimulation.
Results: Vitamin D metabolites did not differ between PCOS and controls; however,
25(OH)D3 correlated with embryo fertilization rates in PCOS patients alone (p = 0.03).
For all subjects, 3epi25(OH)D3 correlated with fertilization rate (p < 0.04) and negatively
with HOMA-IR (p < 0.02); 25(OH)D2 correlated with cleavage rate, G3D3 and blastocyst
(p < 0.05; p < 0.009; p < 0.002, respectively). 24,25(OH)2D3 correlated with AMH,
antral follicle count, eggs retrieved and top quality embryos (G3D3) (p < 0.03; p <
0.003; p < 0.009; p < 0.002, respectively), and negatively with HOMA-IR (p < 0.01).
1,25(OH)2D3 did not correlate with any of the metabolic or embryo parameters. In slim
PCOS, 25(OH)D3 correlated with increased fertilization rates in PCOS, but other vitamin
D parameters did not differ to matched controls.
Conclusion: 3epi25(OH)D3, 25(OH)D2, and 24,25(OH)2D3, but not 1,25(OH)2D3, were
associated with embryo parameters suggesting that vitamin D metabolites other than
1,25(OH)2D3 are important in fertility.
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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is one of the most
common endocrine disorders amongst women of reproductive
age affecting 9–21% of the female population and is the main
cause of anovulatory infertility (1). It is associated with clinical
and biochemical hyperandrogenism, and insulin resistance (IR)
in PCOS is associated with obesity, type 2 diabetes, and
hypercholestrolemia (2). Vitamin D levels are low in 67–85% of
women with PCOS (3), which are suggested to exacerbate IR
and the free androgen index (FAI) in PCOS (4, 5). IR itself is
both independent of and exacerbated by obesity and is present
in 65–80% of women with PCOS (6) and may be improved by
vitamin D replacement (7). In a recent meta-analysis, it was
shown that in weight matched PCOS women, vitamin D was
negatively predicted by weight hip ratio, glucose and LH (8).
Vitamin D deficiency has become the most common
nutritional deficiency throughout the world (9). Studies of sub-
fertile women have demonstrated that vitamin D deficiency
is present in between 58 and 91% of cases (9–12). Obesity
can exacerbate vitamin D deficiency, as a result of decreased
bioavailability from cutaneous and dietary sources because of
deposition in the body fat compartments (13).
Vitamin D3 (cholecalciferol) is endogenously produced or
taken as a dietary supplement, whist vitamin D2 (ergocalciferol)
is derived from the diet (primarily from mushrooms and fungi),
though both are hydroxylated to 25(OH)D3 or 25(OH)D2
by multiple 25-hydroxylases (14, 15) (Figure 1). 25(OH)D is
transported to the kidney and converted to either the active 1,25-
dihydroxyvitamin D (1,25(OH)2D3) by 1 alpha hydroxylase, or
to 24,25-dihydroxyvitamin D (24,25(OH)2D3), that is also active,
by the 24 alpha hydroxylase, in the renal tubular and other
cells widely in the body (Figure 1) (16). It has been recently
reported that extrarenal tissues may also convert 25(OH)D
to 1,25(OH)2D (17). 1,25(OH)2D binds to the vitamin D
receptor (VDR) subsequently heterodimerizes with the retinoid
X receptor for its action that may be effected in several hours (16);
however, a more rapid action has been reported with binding
membrane VDR or through the 1,25D3-membrane-associated,
rapid response steroid-binding protein receptor with activation
of protein kinases A and C (18). Vitamin D receptors have
been located within structures of the female reproductive tract,
including the ovary and endometrium (19, 20).
Vitamin D2 is derived from the diet as ergocalciferol
that has lower binding efficacy to VDR resulting in greater
serum clearance, limiting the formation of 25(OH)D2, though
1,25(OH)2D2 has a high an affinity for VDR as 1,25(OH)2D3
(14, 16). In the United States and other countries vitamin D2 is
available both as a supplement and as a pharmaceutical to treat
vitamin D deficiency.
3- epimerase isomerizes the C-3 hydroxy group of the
natural vitamin D from the α to the β orientation leading to
3epi25(OH)D3 (14, 21) that may be measured inadvertently
whilst measuring 25(OH)D3 (22). 3epi25(OH)D3 is thought to
be less potent physiologically as 25(OH)D3, and 1,25(OH)2-3-
epi-D3 has less affinity to VDR thus less biologically active;
however, the 3-epimer may be as potent as 1,25(OH)2D3 in other
circumstances such as PTH suppression (14, 23) however, data is
sparse on the biological potency of the C3 epimers.
Two IVF cohort studies have suggested that clinical pregnancy
rates were significantly lower in women who were vitamin
D deficient (24, 25), but no differences in the embryological
data have been associated with 25(OH)D3 levels (25). However,
it remains unknown if there is a relationship of baseline
1,25(0H)2D3, 25(OH)D3, 25(OH)D2, 24,25(0H)2D3, or its
epimer 3epi25(OH)D3 to fertilization in non-obese PCOS
subjects when age and weight are matched to control subjects,
and therefore this study was undertaken.
MATERIALS AND METHODS
This prospective cohort study was performed within the Hull IVF
Unit, UK following approval by the Yorkshire and The Humber
NRES ethical committee, UK and all gave their written informed
consent. The PCOS subjects were recruited using the revised 2003
criteria (26), namely any 2 out of 3 criteria were met; menstrual
disturbance (oligo or amenorrhoea), clinical and/or biochemical
signs of androgenism and polycystic ovaries on ultrasound, with
the exclusion of other conditions. All women were on folic
acid 400 mcg daily but no other medication. Exclusion criteria
were patients with diabetes, renal or liver insufficiency, acute or
chronic infections, systemic inflammatory diseases, age <20, age
>45, known Immunological disease.
Sample Collection
A fasting blood sample was taken in the luteal phase of the
cycle before commencing IVF treatment. The bloods were
centrifuged at 3,500 g for 15min and placed into aliquots and
frozen at −80◦C until analysis. The bloods were analyzed
for FSH (Architect analyser, Abbott laboratories, Maidenhead,
United Kingdom), SHBG, insulin (DPC Immulite 200 analyser,
Euro/DPC, Llanberis United Kingdom), and plasma glucose
(Synchron LX20 analyser, Beckman-Coulter, High Wycombe,
United Kingdom). Free androgen index (FAI) was calculated by
dividing the total testosterone by SHBG, and then multiplying
by one hundred. Insulin resistance (IR) was calculated using
the homeostasis model assessment (HOMA-IR). Serum vitamin
D levels and testosterone were quantified using isotope-
dilution liquid chromatography tandem mass spectrometry (LC-
MS/MS). Vitamin D metabolites (1,25(OH)2D3), 25(OH)D2,
25(OH)D3, 24,25(OH)2D3 and 3epi25(OH)D3 and three labeled
internal standards (d6-25(OH)D3, d6-1,25(OH)2D3 and d6-3-
epi-25(OH)D3) were simultaneously extracted from 250 µL
serum using supportive liquid-liquid extraction and Diels-Alder
derivatization prior to LC-MS/MS analysis. Chromatographic
separations were achieved using Hypersil Gold C18 column
(150 × 2.1mm; 1.9µ) at flow rate 0.2 ml/min, operated in
Electrospray Ionization (ESI) positive mode and analyzed by
multiple reaction monitoring (MRM) method. The limit of
quantification (LOQ) for 1,25(OH)2D were 10 pg/mL, 3-epi-
25(OH)D, and 24,25(OH)2D were 50 pg/mL while 25(OH)D3
and 25(OH)D2 were 0.5 and 0.25 ng/mL, respectively. All
methods employed were performed in accordance with the
relevant guidelines and regulations.
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FIGURE 1 | 7-dehydrocholesterol in the skin is converted to previtamin D3 and then is thermally isomerize to vitamin D3. Transport of vitamin D3 from the skin to the
liver is via the Vitamin D binding protein (DBP) transports 25 hydroxy vitamin D (25(OH)D3) to the kidney. 25(OH)D3/DBP is filtered by the glomeruli and 25(OH)D3 is
taken up into the tubular cells, following DBP binding to megalin, a transmembrane protein. 25(OH)D3 undergoes a second hydroxylation step by the
1-alpha-hydroxylase Cyp27B1, converting to the active 1α,25 (OH)2D3, whilst 24 hydroxylase Cyp27A1 converts to 24,25(OH)2D3. Keratinocytes contribute to the
3-epimerase activity converting 25(OH)D3 to 3-epi-25(OH)D3, and 1α,25 (OH)2D3 to 3-epi-1α,25 (OH)2D3, but the exact sites of activity remain unknown.
3epi25(OH)D3 is equally converted by Cyp27A1 and Cyp27B1 as 25(OH)D3. *Vitamin D2 derived from yeasts and fungi (mushrooms) is converted to 25(OH)D2 in the
liver and to 1,25(OH)2D2 and 24,25(OH)2D2 in the kidney (adapted from 14, 16, and 21). It is unclear if the 3-epimers may be back converted.
All patients underwent a standard IVF antagonist protocol.
The patients commenced their rFSH stimulation on day 2 of their
menstrual cycle using either Merional (Pharmasure) or Gonal-F
(Merck Serono). A GnRH antagonist (Cetrotide: Merck Serono)
was used to prevent a premature LH surge.
The patients underwent ultrasound scans from day 7 to
observe the ovarian response to stimulation and were repeated
every 48 h. The scans were used to measure the diameters of
the follicles thus observing response and follicle numbers. Final
maturation was triggered when two ormore leading follicles were
≥18mm using human chorionic gonadotrophin [hCG, Pregnyl
(Merck Sharp and Dohme)].
Transcervical embryo transfer was performed and embryos
were classified using standard criteria (27) at the cleavage stage
(day 2–3 after egg collection) and for blastocyst stage (day 5–6
after egg collection). Top Quality embryos on Day 3 as per Alpha
Consensus (28). Embryo transfers were performed on either day
3 or ideally at day 5 (blastocyst) to give the best chance for
implantation as this timing is similar compared to natural cycle
embryos moving into the uterus.
Data Analysis and Statistics
Statistical analysis was performed using SPSS (v22, Chicago,
Illinios). Descriptive data is presented as mean ± SD for
continuous data and n (%) for categorical data. t-tests or
Mann Whitney tests were used to compare means/medians
where appropriate, and associations used Pearson’s correlation or
Spearman’s correlation as appropriate. A p< 0.05 was considered
to indicate statistical significance. There was no comparative
study on which to base a formal power calculation; therefore,
power and sample size for a pilot study was performed (29);
therefore, to account for a minimum of 20 degrees-of-freedom
to estimate effect size and variability a minimum of 25 patients
per group were required to allow covariate adjustment.
RESULTS
Baseline characteristics of the 59 patients are shown in Table 1
where is can be seen that patients were non-obese, age, and
weight matched. There were significant differences in ovarian
reserve parameters antral follicle count (AFC) and anti-Mullerian
Hormone, (AMH), and androgen status between the groups,
however there was no significant difference in fasting insulin,
HOMA-IR or the vitamin D metabolites (Table 1).
There was a correlation between the levels of 25(OH)D3,
and embryo fertilization rates in PCOS patients (r = 0.44; p
= 0.03) that were not seen in the control group. However,
between the PCOS and control groups there were no differences
for any of the metabolic or embryo parameters for 25(OH)D2,
24R,25(OH)2D3, 1,25(OH)2D3, or 3epi25(OH)D3. When all of
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TABLE 1 | Mean demographics and biochemical data.
Control (n = 30) PCOS (n = 29) p-value
Mean data (±S.D.) Mean data (±S.D.)
Age 32.6 ± 4.7 30.9 ± 4.8 0.14
BMI 25.5 ± 3.6 26.0 ± 3.8 0.56
Menarche 13.0 ± 2.0 13.0 ± 1.1 0.99
Anovulatory 5 25 0.0001***
Duration of subfertility 3.9 ± 1.8 3.4 ± 1.6 0.84
Total antral follicle count 17.2 ± 6.8 38.4 ± 17.8 0.0001***
Fasting insulin (mIU/ml) 7.68 ± 4.0 8.13 ± 4.7 0.69
Fasting glucose (mmol/L) 4.81 ± 0.4 4.62 ± 0.4 0.06
HOMA-IR 1.71 ± 1.0 1.72 ± 1.0 0.97
SHBG 110.9 ± 82.4 63.9 ± 49.8 0.01*
Testosterone (mmol/L) 0.8 ± 0.4 1.4 ± 0.8 0.0004***
Free androgen index 1.35 ± 0.6 4.21 ± 2.9 0.0001***
25-hydroxyvitamin D3
(ng/mL)
46.2 ± 23.5 54.0 ± 27.4 0.24
25-hydroxyvitamin D2
(ng/ml)
0.5 ± 0.3 0.6 ± 0.5 0.73
1,25-dihydroxyvitamin D3 0.03 ± 0.02 0.04 ± 0.2 0.63
24R,25-dihydroxyvitamin
D3
0.8 ± 0.5 1.3 ± 0.6 0.003**
3-epi-25-hydroxyvitamin
D3
0.4 ± 0.4 0.7 ± 1.2 0.89
*p < 0.01, **p < 0.001, ***p < 0.0001.
the subjects were combined there was a correlation between the
levels of 25(OH)D2 and cleavage rate (r = 0.31; p = 0.05), G3D3
(r = 0.40; p = 0.009) and blastocyst (r = 0.40; p = 0.022);
there was a correlation between 3epi25(OH)D3 and fertility rate
(r = 0.33; p < 0.04) and a negative correlation with HOMA-IR
(r = −0.33; p < 0.02); 24R,25(0H)2D3 correlated with AMH
(r = 0.1; p = 0.03) antral follicle count (r = 0.2; p = 0.003),
eggs retrieved (r = 0.14; p = 0.009) and G3D3 (r = 0.22; p =
0.002), and negatively with HOMA-IR (r = −0.07; p < 0.01).
There was no correlation of the active 1,25(0H)2D3 with any of
the metabolic or embryo parameters.
There was a correlation between the levels of 25(OH)D3 with
both 24R,25(OH)2D3 and 3epi25(OH)D3 (r = 0.91, p < 0.001; r
= 0.35, p < 0.015, respectively.
As a cohort, 25-hydroxyvitamin D levels were low did not
differ between the controls and the PCOS group. The Endocrine
Society defines vitamin D deficiency, insufficiency and replete
as (≤20 ng/mL, 20–30 ng/mL and ≥30 ng/mL, respectively (30)
that was reflected in controls and PCOS as, deficient, 51 vs. 41%;
insufficient, 33 vs. 35%; deficient, 10 vs. 24%.
IVF cycle characteristics are represented in Table 2 showing
that the PCOS group had significantly greater numbers of follicles
aspirated and eggs retrieved compared to the controls, and the
mean fertilization and cleavage rates were significantly higher for
the PCOS group, though embryos quality did not differ.
There was a significantly negative correlation between SHBG
and 25-hydroxyvitamin D3 in the PCOS subjects, however after
adjusting for BMI, SHBG was not significantly associated with
25-hydroxyvitamin D3.
TABLE 2 | Mean outcome data for stimulated ovarian cycle for Control and PCOS
groups. G3D3: Top Quality embryos on Day 3 as per Alpha Consensus (28).
Control (N = 30) PCOS (N = 28) p-value
Mean (±S.D.) Mean (±S.D.)
Endometrium at
oocyte retrieval
10.31 ± 1.78 10.72 ± 2.06 0.42
Follicles aspirated 11.47 ± 5.11 15.96 ± 5.30 0.002**
Eggs retrieved 8.47 ± 5.08 11.29 ± 5.02 0.04*
Fertilization 4.82 ± 2.65 8.43 ± 3.87 0.0003***
Cleavage 4.68 ± 2.72 7.26 ± 4.40 0.01*
G3D3 3.00 ± 2.29 4.17 ± 3.47 0.16
Blastocyst 1.46 ± 1.77 2.91 ± 3.01 0.05
PDT 11 10 0.86
Clinical pregnancy 10 7 0.24
*p < 0.01, **p < 0.001, ***p < 0.0001.
DISCUSSION
This study has shown that 25(OH)D3 was associated with
higher fertility rates in PCOS compared to non-obese, age, and
weight matched control subjects, but that this was not seen
for the other vitamin D metabolites. This was surprising given
that there was no difference in the 25(OH)D3 levels between
the PCOS and control group; however, it is recognized that
ova in PCOS may be at a less mature stage compared to
normal and therefore there is a possibility that they may be
more 25-hydroxyvitamin D responsive to allow those ovum
within the stimulated follicles to reach a more mature stage
prior to ovum retrieval, resulting in a greater capability to
achieve fertilization. PCOS women typically produced more
poor quality oocytes, with lower fertilization, cleavage and
implantation rates (31, 32). The impaired oocyte maturation
and resultant embryonic developmental competence in PCOS
women is possibly due to the abnormal endocrine/paracrine
functions and the environment within the follicle at the time of
folliculogenesis (33, 34). No differences in the embryological data
for 25(OH)D3 were found, in accord with others (25). It may
have been speculated that the active 1,25(OH)2D3 may have a
greater influence on fertility at higher levels, but this was not seen
in this study, with no correlation with fertilization or embryo
data. Vitamin D is involved in the regulation of AMH and FSH
gene expression (31, 35), and high dose 25(OH)D3 has been
shown to increase serum AMH levels in vitamin D insufficiency
(36). In this study only the metabolite 24R,25(OH)2D3 correlated
with AMH and antral follicle count; 24R,25(OH)2D3 is an active
metabolite [It can be converted to 1,24,25-trihydroxyvitamin D3
through the C24 oxidation pathway (37)] as it has been shown
to induce non-genomic signaling pathways and suppresses Apo
A-1 in hep G cells (38), may have a physiological role in the
growth plate formation (14), therefore a direct effect on the
ovary cannot be excluded. However, 24,25 dihydroxyvitamin D
is associated with blood levels of 25-hydroxyvitamin D and given
that both were very significantly associated it is unlikely that
24R,25(OH)2D3 was having a unique biological effect and indeed
was dependent on serum 25(OH)D3 levels.
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There was a positive association for an increase in overall
fertility rate with the 3epi25(OH)D3 that was not seen for the
other vitamin D metabolites. Little is known about the epimers
of vitamin D, with the assumption that they are biologically less
potent (21, 23), but whilst that is likely for bone metabolism it
may not be the case for ovarian effects. Epimers are compounds
that have identical structure (and therefore identical molecular
weight) with the exception of a stereochemical difference at one
site. Other than the measurement of 3epi25(OH)D3 to enable
the more accurate determination of 25(OH)D3, in children where
they have been shown to be higher, there has been little research
done on the C3 epimers (39) in order to know the significance
of this observation on fertility, but it is of interest to note
that serum lipids were discrepant for 25(OH)D epimeric forms
suggesting a differential effect (40). However, 3epi25(OH)D3 is
associated with blood levels of 25-hydroxyvitamin D and given
that both were very significantly associated it is unlikely that
3epi25(OH)D3 was having a unique biological effect and indeed
was dependent on serum 25(OH)D3 levels.
Whole group analysis for 25(OH)D2, but not 25(OH)D3 was
positively associated with increased cleavage rate, G3D3 and
blastocyst, though overall embryo quality did not differ. Whilst
vitamin D3 supplements are better than vitamin D2 to raise
vitamin D levels (41, 42), their biological effects may not be
the same in different systems (43), and their differential effect
in the ovary needs to be clarified. The role of vitamin D in
fertilization remains controversial and the specific roles of 25-
hydroxyvitamin D levels largely unknown. Observational studies
have reported vitamin D levels within serum and follicular fluid
to be highly correlated and that those with higher serum and
follicular fluid levels of vitamin D had significantly higher clinical
pregnancy rates (12). Other studies have found no correlation
between serum and follicular fluid levels of vitamin D and
IVF outcomes (10, 35, 44). Conversely, two cohort studies
comparing serum vitaminD levels and pregnancy rates in women
undergoing fresh IVF showed that clinical pregnancy rates were
significantly lower in women who were vitamin D deficient
(24, 25). Given the controversy, the implication of this data is
that in slim PCOS women undergoing IVF that their vitamin D
status should be determined, vitamin D replacement undertaken
for those deficient prior to IVF may be of benefit, or at least do
not harm, until future clarification becomes available.
These data suggest that vitamin D deficiency may not be a
homogeneous entity but rather may depend on the different
vitamin D metabolites present giving resultants effects, and
therefore may account for the heterogeneity and controversy
surrounding vitamin D deficiency effects and the response to
replacement (42, 45). Whilst the effects of vitamin D and its
metabolites on bone and calcium metabolism are well-known,
vitamin D metabolite effects on other systems may not be
directly equipotent for each metabolite or comparable. For
example 1,25(OH)2-3-epi-D3 may be biologically less active
than 1,25(OH)2D3, for increasing calcium, but may have
greater PTH suppression (39). However, the kidneys produce
1,25-dihydroxyvitamin D for regulating calcium and bone
metabolism (46). Therefore, measuring a blood level of 1,25-
dihydroxyvitamin D may not reflect its other biologic functions,
but rather local production of 1,25-dihydroxyvitamin D may
have its major benefit (47). Our observation that higher blood
levels of 25-hydroxyvitamin D are related to the outcome
measures could also be due to the higher substrate availability
for the local production of 1,25-dihydroxyvitamin D rather than
25-hydroxyvitamin D having a direct effect.
When weight and aged matched then there was no difference
in vitamin D metabolite levels between PCOS and normal
women. These results differ from previous studies that found
Vitamin D deficiency to be more common in PCOS subjects
(48); however, in this study the PCOS patients were specifically
non-obese and it is well-recognized that vitamin D levels fall
in obesity that may account for this observation (6). Negative
correlations with HOMA-IR were seen for both 24R,25(OH)2D3,
and 3epi25(OH)D3, but no association was seen for either
25(OH)D2 or 25(OH)D3, suggesting that an association with
insulin resistance may depend on the metabolites present. There
were no correlations between testosterone or oocyte quality in the
PCOS patients in this study These observations are in accord with
some studies, though not with others (4, 49); however, in those
reported studies patients were not intentionally weight matched.
High dose 25(OH)D3 replacement was not associated with an
improvement in insulin sensitivity in PCOS subjects (50).
This study was specifically designed to look at the relationship
of vitamin D levels with fertilization rates and therefore was not
powered to look at pregnancy rates that would require a much
larger sample population. Furthermore, the overall sample size
is small and further work is needed, particularly to determine if
these findings are true for the differing PCOS phenotypes within
the Rotterdam criteria. However, the strengths of this study were
that the patients were age and weight matched from the same
ethnic background and that all of the vitamin Dmetabolites were
measured by state of the art methods.
In conclusion, non-obese age and weight matched PCOS
women showed that 25(OH)D3 was associated with the
fertilization rate, compared to controls; however, vitamin D
metabolites were associated with embryology parameters and
HOMA-IR, suggesting a possible relationship between differing
vitamin D metabolites, oocyte maturation and insulin sensitivity
in non-obese PCOS patients.
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